Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Jurnal Ilmu Kefarmasian Indonesia Jurnal Ilmiah Medicamento Jurnal Farmasi dan Sains Indonesia (JFSI)
ARIEF NURROCHMAD
UNIVERSITAS GADJAH MADA
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Medicine & Pharmacology Neuroscience Public Health

Published : 5 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 5 Documents
Search

 1 
Konstruksi dan Validasi Protokol Skrining Virtual Berbasis Struktur dengan Kode PDB 3MQE, 3NTG, dan 3LN0 untuk Penemuan Inhibitor Siklooksigenase-2 (COX-2) ESTI MUMPUNI; ARGUN WIDARSA; YANTI SUSILAWATI; OISAN OISAN; ARIEF NURROCHMAD; HARNO DWI PRANOWO; UMAR ANGGARA JENIE; ENADE PERDANA ISTYASTONO
JURNAL ILMU KEFARMASIAN INDONESIA Vol 12 No 1 (2014): JIFI
Publisher : Fakultas Farmasi Universitas Pancasila

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1025.318 KB)

Abstract

Cyclooxygenase-2 (COX-2) inhibitors are high demand drugs in the market. However, available COX-2 inhibitors nowadays have many side effects. Therefore, there is still a need to develop more potent selective COX-2 inhibitors and one of the method that has been prove the effectivity and eficiency for new drugs research is in silico. Structure-based virtual screening (SBVS) protocols were developed to find COX-2 inhibitors using the Protein-Ligand ANT System (PLANTS) docking software, SPORES, BKChem and Open Babel. The directory of useful decoys (DUD) dataset for COX-2 was used to validate the protocols retrospectively; the DUD consist of 426 known COX-2 inhibitors and 13289 decoys. Based on criteria value of EF20% and EFmax used in the article from Huang et al (2006) and Yuniarti et al (2011), two validated protocol, AYO_COX2_v.1.1 and AYO_COX2_v.1.2 , showed good results
Kurkumin Analog, PGV-0 dan GVT-0 Menghambat Absorpsi Kolesterol dengan Penghambatan Aktivitas Enzim Li IKA PUSPITA SARI; ARIEF NURROCHMAD; IRFAN MURIS SETIAWAN; SARDJIMAN SARDJIMAN
JURNAL ILMU KEFARMASIAN INDONESIA Vol 11 No 2 (2013): JIFI
Publisher : Fakultas Farmasi Universitas Pancasila

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (337.073 KB)

Abstract

Curcumin has been known to reduce cholesterol levels in hyperlipidemic state. Faculty of Pharmacy Universitas Gadjah Mada (UGM) synthesized curcumin analogues namely PGV-0 and GVT-0. Like curcumin, both PGV-0 and GVT-0 exhibit anti-inflammatory activities. The aims of this study were to determine the effect and the mechanism of curcumin analogues PGV-0 and GVT-0 on regulation of cholesterol levels in serum. This study was aimed to examine whether PGV-0 and GVT-0 affected cholesterol levels through cholesterol absorption which is regulated by lipase enzyme. To determine the reduction in cholesterol levels, rats were feed with high fat diet (HFD) for 45 days. PGV-0 and GVT-0 were given on day 31-45 at doses of 40 mg/kg bw and 60 mg/kg bw consecutively. Total cholesterol and lipase activity in serum were measured and then statistically analyzed using ANOVA and t-test. The increase of cholesterol levels was markedly reduced by the treatment with both curcumin analogues. Furthermore, lipase activity was clearly inhibited by the treatment with PGV-0 and GVT-0, suggesting that these compounds inhibit cholesterol levels through the reduction of lipase enzyme activity
Virtual Screening and Bonding Mode Elucidation of Curcumin Analogue in Cyclooxygenase-2 Enzyme Using EE_COX2_V.1.0 Protocol ESTI MUMPUNI; ARIEF NURROCHMAD; UMAR ANGGARA JENIE; HARNO DWI PRANOWO
JURNAL ILMU KEFARMASIAN INDONESIA Vol 13 No 2 (2015): JIFI
Publisher : Fakultas Farmasi Universitas Pancasila

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (487.851 KB)

Abstract

Kurkumin adalah senyawa fenol bewarna kuning yang terkandung dalam Curcuma longa. Kurkumin diketahui memiliki aktivitas biologi antara lain sebagai inhibitor beberapa enzim metabolisme. Modifikasi struktur kurkumin telah banyak dilakukan. Pada penelitian ini dilakukan penapisan virtual dan elusidasi moda ikatan analog kurkumin menggunakan EE_COX2_V.1.0 sebagai protokol skrining virtual berbasis struktur yang telah tervalidasi. Pengaturan simulasi docking dilakukan menggunakan berbagai aplikasi yang terintegrasi seperti SPORES, PLANTS, BKchem, OpenBabel dan Pymol yang dapat mengidentifikasi senyawa inhibitor siklooksigenase-2 (COX-2). Dari hasil penapisan virtual didapatkan senyawa demetoksikurkumin dengan 3 residu asam amino dan 1,7-bis(3-metoksifenil)-1,6-heptadien-3,5-dion dengan 6 residu asam amino aktif in silico sebagai inhibitor COX-2.
AKTIVITAS FRAKSI-FRAKSI EKSTRAK ETANOL DAUN MURBEI (Morus australis Poir.) TERHADAP FUNGSI HATI TIKUS PUTIH MODEL HIPERKOLESTEROLEMIA YANG DIBERI DIET TINGGI LEMAK Nurul Huda; Rina Herowati; Arief Nurrochmad
Jurnal Farmasi & Sains Indonesia Vol 3 No 2 (2020)
Publisher : LPPM Sekolah Tinggi Ilmu Farmasi Nusaputera

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Daun murbei mengandung flavonoid, alkaloid, dan polifenol. Tujuan dari penelitian ini adalah untuk mengetahui aktivitas fraksi-fraksi ekstrak etanol daun murbei terhadap fungsi hati tikus putih model hiperkolesterolemia yang diberi diet tinggi lemak. Hewan uji yang digunakan adalah tikus jantan wistar sebanyak 35 ekor dibagi menjadi 7 kelompok, masing-masing kelompok terdiri dari 5 ekor tikus. Kelompok I kontrol normal, kelompok II kontrol negatif, kelompok III kontrol positif (simvastatin 0,9 mg/Kg BB), kelompok IV ekstrak etanol dosis 500 mg/Kg BB, kelompok V fraksi n-heksan dosis 60 mg/Kg BB , kelompok VI fraksi etil asetat dosis 40 mg/Kg BB , dan kelompok VII fraksi air dosis 400 mg/Kg BB. Semua kelompok diberikan pakan diet tinggi lemak+PTU selama 28 hari kecuali kelompok normal diberikan pakan standar. Pemberian fraksi uji dilakukan selama 14 hari. Hasil penelitian menunjukkan bahwa fraksi etil asetat dengan dosis 40 mg/kg BB merupakan fraksi yang paling optimal dalam menurunkan kadar ALT dan AST pada tikus yang diberi diet tinggi lemak dan PTU.
Understanding the Safety Profile of Imatinib in Asian Chronic Myeloid Leukemia Patients: A Systematic Review Niky Budiarti; Zullies Ikawati; Arief Nurrochmad; Thendi Abdul Arief
Jurnal Ilmiah Medicamento Vol 12 No 1 (2026): Jurnal Ilmiah Medicamento (In progress)
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v12i1.13296

Abstract

Background: The treatment of chronic myeloid leukemia has advanced substantially since the introduction of tyrosine kinase inhibitors, particularly imatinib. However, adverse events associated with imatinib may affect adherence and quality of life, highlighting the importance of understanding safety outcomes across populations.Objective: This systematic review aimed to synthesize evidence on hematologic and non-hematologic adverse events associated with imatinib use among chronic myeloid leukemia patients in Asia.Methods: A systematic literature search was conducted in PubMed, Scopus, and ScienceDirect for studies published between January 2020 and July 2025. Eligible studies were synthesized narratively due to methodological heterogeneity. Adverse events were extracted as reported and graded using standardized toxicity criteria, and causality assessment was applied when available. Study quality was evaluated using established critical appraisal tools. Five studies from India, China, and Taiwan met the inclusion criteria.Results: The most frequent hematologic adverse event was anemia, followed by neutropenia and thrombocytopenia. Common non-hematologic adverse events included gastrointestinal symptoms, peripheral or periorbital edema, muscle cramps, and hyperpigmentation, with regional variations. Most events were mild to moderate (grades 1–2), while severe fluid retention, including pleural and pericardial effusions, was reported in isolated cases. No studies reported permanent discontinuation of imatinib due to adverse events.Conclusion: This review summarizes imatinib-related adverse events among chronic myeloid leukemia patients from selected Asian regions—East and South Asia, specifically India, China, and Taiwan—showing predominantly mild to moderate toxicities and providing practice-informed insights for clinical monitoring. However, the absence of data from other Asian regions precludes generalization to the entire Asian continent.
Co-Authors ARGUN WIDARSA Enade Perdana Istyastono Esti Mumpuni ESTI MUMPUNI Harno Dwi Pranowo IKA PUSPITA SARI Irfan Muris Setiawan Niky Budiarti Nurul Huda OISAN OISAN Sardjiman Sardjiman Thendi Abdul Arief Umar Anggara Jenie YANTI SUSILAWATI ZULLIES IKAWATI